Inger Westborg
YOU?
Author Swipe
View article: Intravitreal anti‐vascular endothelial growth factor injections and risks of stroke in patients with neovascular age‐related macular degeneration—A registry‐based cohort study
Intravitreal anti‐vascular endothelial growth factor injections and risks of stroke in patients with neovascular age‐related macular degeneration—A registry‐based cohort study Open
Background Intravitreal Anti‐Vascular Endothelial Growth Factor (VEGF) rescues retinal vasculatures and prevents disease progression in patients with neovascular Age‐Related Macular Degeneration (nAMD). However, systemic anti‐VEGF may incr…
View article: Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study
Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study Open
Purpose To investigate the eligibility for faricimab in a real-world diabetic macular oedema (DMO) population to the YOSEMITE and RHINE trials, and to compare the eligible DMO populations to the trial populations. Design, settings and part…
View article: Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry
Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry Open
Purpose To analyse the impact on cost if faricimab is used as the first‐line treatment for neovascular age‐related macular degeneration (nAMD) compared to standard treatment with bevacizumab. Methods Retrospective registry study including …
View article: What about the fellow eye in treatment of neovascular age‐related macular degeneration? Analysis of data from the Swedish macula register
What about the fellow eye in treatment of neovascular age‐related macular degeneration? Analysis of data from the Swedish macula register Open
Purpose To analyse the development of neovascular age‐related macular degeneration (nAMD) in the fellow eye in patients initially presenting with unilateral nAMD, using data from the Swedish Macula Register. Methods This observational stud…
View article: Exploration of real‐world outcomes and treatment patterns in patients treated with anti‐vascular endothelial growth factors for neovascular age‐related macular degeneration in Sweden
Exploration of real‐world outcomes and treatment patterns in patients treated with anti‐vascular endothelial growth factors for neovascular age‐related macular degeneration in Sweden Open
Purpose To analyse and compare the number and interval of anti‐vascular endothelial growth factor (anti‐VEGF) injections in neovascular age‐related macular degeneration (nAMD), as well as the visual development in patients followed up for …
View article: Follow-Up After Cataract Surgery – Comparison of the Practice in Two Institutions with the Aim of Optimize the Routine
Follow-Up After Cataract Surgery – Comparison of the Practice in Two Institutions with the Aim of Optimize the Routine Open
Inger Westborg, Eva Mönestam Department of Clinical Sciences/Ophthalmology, Faculty of Medicine, Umeå University, Umeå S-901 85, SwedenCorrespondence: Inger WestborgDepartment of Clinical Sciences/Ophthalmology, Faculty of Medicine, Umeå U…
View article: <p>Follow-Up After Cataract Surgery – Comparison of the Practice in Two Institutions with the Aim of Optimize the Routine</p>
Follow-Up After Cataract Surgery – Comparison of the Practice in Two Institutions with the Aim of Optimize the Routine Open
Without compromising patient safety, it is possible to reduce the burden of postoperative visits in cases with uncomplicated cataract surgery. A reduction in the number of visits is obtained only if the standard routine is no planned posto…
View article: Treatment of age‐related macular degeneration after cataract surgery: a study from the Swedish National Cataract and Macula Registers
Treatment of age‐related macular degeneration after cataract surgery: a study from the Swedish National Cataract and Macula Registers Open
Purpose To characterize pre‐ and perioperative factors associated with treatment for wet age‐related macular degeneration (wet AMD) after cataract surgery. Methods This register‐based cohort study with data from the Swedish National Catara…
View article: Twelve per cent of 6142 eyes treated for neovascular age‐related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)
Twelve per cent of 6142 eyes treated for neovascular age‐related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR) Open
Purpose To analyse characteristics from the SMR to explore the risk factors for visual acuity (VA) below ≤ 35 letters of the Early Treatment Diabetic Retinopathy Study (ETDRS) due to nAMD during a two‐year follow‐up. Methods This study eva…
View article: Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age‐related macular degeneration: data from the <scp>INSIGHT</scp> study using the Swedish Macula Register
Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age‐related macular degeneration: data from the <span>INSIGHT</span> study using the Swedish Macula Register Open
Purpose To assess mean change in visual acuity ( VA ) overall and stratified by baseline VA after 1 and 2 years’ treatment with aflibercept in a real‐life setting. Methods This was an observational cohort study using nationwide data from t…
View article: Risk for low visual acuity after 1 and 2 years of treatment with anti-VEGF. Comparison of different agents : Ranibizumab, Aflibercept, and Bevacizumab
Risk for low visual acuity after 1 and 2 years of treatment with anti-VEGF. Comparison of different agents : Ranibizumab, Aflibercept, and Bevacizumab Open
Purpose : To analyze the risk factors for low visual acuity and compare the visual acuity, number of visits and injections received by patients on different anti-vascular endothelial growth factor ...
View article: Safety and efficacy in the cataract surgery process
Safety and efficacy in the cataract surgery process Open
Background Cataract and age-related macular degeneration (AMD) are two major causes for visual impairment in the elderly. Cataract surgery is one of the most common surgical interventions performed in the western world. As a consequence of…
View article: Treatment for neovascular age‐related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register
Treatment for neovascular age‐related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register Open
Purpose To present Swedish Macula Register (SMR) data regarding treatment of neovascular age‐related macular degeneration (AMD) in clinical practice since 2008. Methods A retrospective register‐based study was conducted. Evaluation of base…
View article: RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Open
Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. Methods: Data from the Swedish Macula Register on the treatment…
View article: Reduced occurrence of severe visual impairment after introduction of anti‐Vascular Endothelial Growth Factor in wet age‐related macular degeneration – a population‐ and register‐based study from northern Sweden
Reduced occurrence of severe visual impairment after introduction of anti‐Vascular Endothelial Growth Factor in wet age‐related macular degeneration – a population‐ and register‐based study from northern Sweden Open
Purpose To study the occurrence of severe visual impairment ( SVI ) and treatment outcome at 12 months in patients treated for wet age‐related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals t…